Literature DB >> 3147725

Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing.

D K Yu1, R L Williams, L Z Benet, E T Lin, D H Giesing.   

Abstract

Single dose oral nitroglycerin (GTN) was administered to six healthy subjects as 6.5, 9.0, and 13.0 mg aqueous solutions in sequential study phases to characterize the oral pharmacokinetics of GTN and the dinitrate metabolites. Blood samples were collected periodically up to 10 h. Plasma concentrations of GTN were measurable in some subjects up to 1/2 and 1 h, respectively, after the 9.0 and 13.0 mg dose. The mean GTN Cmax values of the three solution doses were 0.28, 0.78, and 0.42 ng ml-1 in ascending dosage. The erratic nature of GTN plasma profiles prevented meaningful pharmacokinetic analysis, although tmax was consistently 5 min. In all three treatments, both GTN metabolites (1,2- and 1,3-glyceryldinitrates, GDNs) peaked at about 20 min, followed by a distributive phase and a log-linear decline in concentrations. Terminal half-lives for both GDNs were approximately 50 min in all three doses. The plasma concentrations of the metabolites were higher than nitroglycerin with 1,2-GDN exhibiting the highest overall profile.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147725     DOI: 10.1002/bod.2510090606

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  11 in total

1.  Pharmacological activity of the dinitrate metabolites of nitroglycerin following their oral administration to healthy volunteers.

Authors:  M Gumbleton; L Z Benet
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Novel pharmacokinetic modelling of transdermal nitroglycerin.

Authors:  B Auclair; G Sirois; A H Ngoc; M P Ducharme
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway.

Authors:  Mao Mao; Varadarajan Sudhahar; Kristine Ansenberger-Fricano; Denise C Fernandes; Leonardo Y Tanaka; Tohru Fukai; Francisco R M Laurindo; Ronald P Mason; Jeannette Vasquez-Vivar; Richard D Minshall; Krisztian Stadler; Marcelo G Bonini
Journal:  Free Radic Biol Med       Date:  2011-10-07       Impact factor: 7.376

Review 4.  Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

Authors:  P A Todd; K L Goa; H D Langtry
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites.

Authors:  Satoru Hashimoto; Atsuko Kobayashi
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of nitrates.

Authors:  M G Bogaert
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

7.  Variable glyceryl dinitrate formation following infusions of glyceryl trinitrate at different vascular sites in the rat.

Authors:  E Nakashima; D T Lau; L Z Benet
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

Review 8.  Organic nitrate metabolism and action: toward a unifying hypothesis and the future-a dedication to Professor Leslie Z. Benet.

Authors:  Nathaniel A Page; Ho-Leung Fung
Journal:  J Pharm Sci       Date:  2013-05-13       Impact factor: 3.534

9.  Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations.

Authors:  R L Williams; K M Thakker; V John; E T Lin; W Liang-Gee; L Z Benet
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

10.  Simultaneous pharmacodynamic modeling of the non-steady-state effects of three oral doses of 1,3-glyceryl dinitrate upon blood pressure in healthy volunteers.

Authors:  M Gumbleton; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.